%0 Generic
%A Schutz, Charlotte
%A Chirehwa, Maxwell
%A Barr, David
%A Ward, Amy
%A Janssen, Saskia
%A Burton, Rosie
%A J. Wilkinson, Robert
%A Shey, Muki
%A Wiesner, Lubbe
%A Denti, Paolo
%A McIlleron, Helen
%A Maartens, Gary
%A Meintjes, Graeme
%D 2019
%T Khayelitsha Hospital TB study pharmacokinetic variables: Non compartmental analysis
%U https://zivahub.uct.ac.za/articles/dataset/Khayelitsha_Hospital_TB_study_pharmacokinetic_variables_Non_compartmental_analysis/9541991
%R 10.25375/uct.9541991.v1
%2 https://zivahub.uct.ac.za/ndownloader/files/17173031
%K HIV-TB
%K pharmacokinetics parameters
%K Clinical Pharmacology and Therapeutics
%X
Human immunodeficiency virus associated tuberculosis (HIV-TB) comprise 10% of global tuberculosis cases but contribute a disproportionate 22% of global tuberculosis mortality. HIV-infected patients hospitalized with HIV-TB have high high case fatality rates despite treatment and often present with a clinical picture compatible with sepsis. There is paucity of data in critically ill HIV-infected patients admitted to hospital at the time of tuberculosis diagnosis. Improved, evidence-based treatment interventions in this patient group are urgently needed to improve survival.
We performed intensive pharmacokinetic studies (from 0-8 hours) in a high burden setting (Khayelitsha Hospital, Cape Town), within the routine service. We assessed rifampicin, isoniazid and pyrazinamide exposure in a group of hospitalized HIV-TB patients and a group of outpatients on the third day of standard antituberculosis therapy using non-compartmental analysis. We followed hospitalized patients for 12 weeks to asses survival. We compared pharmacokinetic exposures in hospitalized patients and outpatients; hospitalized patients who survived twelve weeks and those who died; and hospitalized patients presenting with high lactate (more than 2.2 mmol/L) and patient presenting with normal lactate.
%I University of Cape Town